253155-01-0

Upstream product

• 229328-24-9 C₂₆H₂₉Cl₂N₃O₆S 

Downstream Products

• 253152-20-4 C₂₄H₂₅Cl₂N₃O₆S 
• 253152-22-6 4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S)-3-[((1,1-dimethylethyl)amino)carbonyl]-4-thiazolidinyl]carbonyl]-L-phenylalanine Methyl Ester 
• 253152-23-7 4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S)-3-[(diethylamino)carbonyl]-4-thiazolidinyl]carbonyl]-L-phenylalanine Methyl Ester 
• 253152-24-8 C₂₆H₂₇Cl₂N₃O₇S 
• 253152-18-0 4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S)-3-(methylsulfonyl)-4-thiazolidinyl]carbonyl]-L-phenylalanine Methyl Ester 

Relevant academic research and scientific papers

Inhibitors of α4β1 mediated cell adhesion

The present invention relates to compound of formula (I), that are potent inhibitors of α4β1mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treating or preventing α4β1adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained in the present specification.